JP2021533805A5 - - Google Patents
Info
- Publication number
- JP2021533805A5 JP2021533805A5 JP2021510015A JP2021510015A JP2021533805A5 JP 2021533805 A5 JP2021533805 A5 JP 2021533805A5 JP 2021510015 A JP2021510015 A JP 2021510015A JP 2021510015 A JP2021510015 A JP 2021510015A JP 2021533805 A5 JP2021533805 A5 JP 2021533805A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nucleic acid
- cpg
- sequence
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024060919A JP2024102065A (ja) | 2018-08-24 | 2024-04-04 | 最適化されたプロモーター配列、イントロンを含まない発現構築物及び使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862722547P | 2018-08-24 | 2018-08-24 | |
| US62/722,547 | 2018-08-24 | ||
| US201862725096P | 2018-08-30 | 2018-08-30 | |
| US62/725,096 | 2018-08-30 | ||
| US201862784116P | 2018-12-21 | 2018-12-21 | |
| US62/784,116 | 2018-12-21 | ||
| PCT/US2019/048032 WO2020041773A1 (en) | 2018-08-24 | 2019-08-23 | Optimized promoter sequences, intron-free expression constructs and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024060919A Division JP2024102065A (ja) | 2018-08-24 | 2024-04-04 | 最適化されたプロモーター配列、イントロンを含まない発現構築物及び使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021533805A JP2021533805A (ja) | 2021-12-09 |
| JP2021533805A5 true JP2021533805A5 (https=) | 2022-04-26 |
Family
ID=69591143
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510015A Pending JP2021533805A (ja) | 2018-08-24 | 2019-08-23 | 最適化されたプロモーター配列、イントロンを含まない発現構築物及び使用方法 |
| JP2024060919A Pending JP2024102065A (ja) | 2018-08-24 | 2024-04-04 | 最適化されたプロモーター配列、イントロンを含まない発現構築物及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024060919A Pending JP2024102065A (ja) | 2018-08-24 | 2024-04-04 | 最適化されたプロモーター配列、イントロンを含まない発現構築物及び使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12290574B2 (https=) |
| EP (1) | EP3840775A4 (https=) |
| JP (2) | JP2021533805A (https=) |
| CN (1) | CN113226352B (https=) |
| AU (2) | AU2019325688B2 (https=) |
| BR (1) | BR112021003399A2 (https=) |
| CA (1) | CA3111047A1 (https=) |
| MX (1) | MX2021002198A (https=) |
| TW (1) | TW202012425A (https=) |
| WO (1) | WO2020041773A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3635009T3 (da) | 2017-06-07 | 2026-03-30 | Regeneron Pharma | Sammensætninger og fremgangsmåder til internalisering af enzymer |
| US12258597B2 (en) | 2018-02-07 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for therapeutic protein delivery |
| BR112020023145A2 (pt) | 2018-05-17 | 2021-02-02 | Regeneron Pharmaceuticals, Inc. | anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto |
| GB201813528D0 (en) | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
| CA3218126A1 (en) * | 2021-05-07 | 2022-11-10 | Matthew MANGANIELLO | Lyophilized non-viral dna vector compositions and uses thereof |
| KR20240005903A (ko) * | 2021-05-07 | 2024-01-12 | 제너레이션 바이오 컴퍼니 | 백신 전달을 위한 비바이러스성 dna 벡터 |
| KR20250007615A (ko) * | 2022-04-28 | 2025-01-14 | 조인트 스탁 컴퍼니 "바이오케드" | Fviii-bdd를 인코딩하는 코돈 최적화된 핵산 |
| CN115948408A (zh) * | 2022-09-23 | 2023-04-11 | 上海信致医药科技有限公司 | 改进的人凝血因子viii基因表达盒及其应用 |
| EP4598590A1 (en) * | 2022-10-08 | 2025-08-13 | Lingyi Biotech Co., Ltd. | Construct for enhancing gene expression |
| WO2025264490A1 (en) * | 2024-06-17 | 2025-12-26 | Spark Therapeutics, Inc. | Dna promoters |
| CN119242712A (zh) * | 2024-09-27 | 2025-01-03 | 南京师范大学 | 特异性靶向骨骼肌细胞的携带miRNA-486基因的腺相关病毒载体、药物组合物 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020065236A1 (en) | 1998-09-09 | 2002-05-30 | Yew Nelson S. | CpG reduced plasmids and viral vectors |
| JP2008521575A (ja) * | 2004-12-01 | 2008-06-26 | ジェンザイム・コーポレイション | 肝臓を標的とした遺伝物質の送達方法 |
| US8008468B2 (en) * | 2005-02-16 | 2011-08-30 | Benitec, Inc. | RNAi expression constructs with liver-specific enhancer/promoter |
| WO2011109380A1 (en) | 2010-03-01 | 2011-09-09 | The Children's Hospital Of Philadelphia | Nucleic acids for targeting multiple regions of the hcv genome |
| US20140271550A1 (en) | 2013-03-14 | 2014-09-18 | The Trustees Of The University Of Pennsylvania | Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune Responses |
| EP3133923B1 (en) * | 2014-04-24 | 2020-06-03 | University of Florida Research Foundation, Inc. | Aav-based gene therapy for multiple sclerosis |
| US10214731B2 (en) * | 2015-05-28 | 2019-02-26 | Cornell University | Adeno-associated virus mediated delivery of C1E1 as a therapy for angioedema |
| MX390848B (es) | 2015-06-23 | 2025-03-21 | Childrens Hospital Philadelphia | Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos. |
| TW202446416A (zh) * | 2015-09-24 | 2024-12-01 | 美商拜奧馬林製藥公司 | 腺相關病毒因子viii載體、相關病毒粒子及包含其之治療調配物 |
| MY189674A (en) | 2015-10-28 | 2022-02-24 | Sangamo Therapeutics Inc | Liver-specific constructs, factor viii expression cassettes and methods of use thereof |
| PE20231949A1 (es) * | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA |
| EP3293260A1 (en) | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
| WO2018046774A1 (en) | 2016-09-12 | 2018-03-15 | Genethon | Acid-alpha glucosidase variants and uses thereof |
| EP3293259A1 (en) | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
| EP3293203A1 (en) | 2016-09-12 | 2018-03-14 | Genethon | Acid-alpha glucosidase variants and uses thereof |
| CN111902539B (zh) | 2018-02-07 | 2025-05-16 | 吉尼松公司 | 杂合调控元件 |
| CA3089587A1 (en) | 2018-02-08 | 2019-08-15 | Sangamo Therapeutics, Inc. | Engineered target specific nucleases |
| MY207355A (en) | 2018-05-16 | 2025-02-21 | Spark Therapeutics Inc | Codon-optimized acid lpha-glucosidase expression cassettes and methods of using same |
| EP3829619A4 (en) | 2018-07-27 | 2022-05-18 | REGENXBIO Inc. | TREATMENT OF IVA MUCOPOLYSACCHARIDOSIS |
| KR20210148101A (ko) | 2019-02-04 | 2021-12-07 | 프리라인 테라퓨틱스 리미티드 | 폴리뉴클레오티드 |
| AU2019428629A1 (en) | 2019-02-06 | 2021-01-28 | Sangamo Therapeutics, Inc. | Method for the treatment of mucopolysaccharidosis type I |
| JP7654562B2 (ja) | 2019-04-19 | 2025-04-01 | ジェネトン | 線維芽細胞増殖因子２３関連低リン血症性疾患の遺伝子療法 |
| WO2020219868A1 (en) | 2019-04-24 | 2020-10-29 | Regenxbio Inc. | Fully-human post-translationally modified antibody therapeutics |
| EP4004214A1 (en) | 2019-07-26 | 2022-06-01 | RegenxBio Inc. | Engineered nucleic acid regulatory element and methods of uses thereof |
| WO2021078834A1 (en) | 2019-10-22 | 2021-04-29 | Genethon | Chimeric acid-alpha glucosidase polypeptides and uses thereof |
| JP7719060B2 (ja) | 2019-10-22 | 2025-08-05 | ジェネトン | キメラポリペプチド及びその使用 |
| CN114929735A (zh) | 2019-11-01 | 2022-08-19 | 自由行疗法有限公司 | 因子viii构建体 |
| WO2021087361A1 (en) | 2019-11-01 | 2021-05-06 | Sangamo Therapeutics, Inc. | Zinc finger nuclease variants for treating or preventing lysosomal storage diseases |
| EP3913060A1 (en) | 2020-05-22 | 2021-11-24 | Genethon | Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapy |
| GB202009741D0 (en) | 2020-06-25 | 2020-08-12 | Freeline Therapeutics Ltd | Polynucleotide |
| BR112023016997A2 (pt) | 2021-02-26 | 2023-11-07 | Logicbio Therapeutics Inc | Fabricação e uso de vetores aav recombinantes |
-
2019
- 2019-08-23 BR BR112021003399-8A patent/BR112021003399A2/pt unknown
- 2019-08-23 AU AU2019325688A patent/AU2019325688B2/en active Active
- 2019-08-23 WO PCT/US2019/048032 patent/WO2020041773A1/en not_active Ceased
- 2019-08-23 EP EP19852321.9A patent/EP3840775A4/en active Pending
- 2019-08-23 CN CN201980070435.4A patent/CN113226352B/zh active Active
- 2019-08-23 CA CA3111047A patent/CA3111047A1/en active Pending
- 2019-08-23 JP JP2021510015A patent/JP2021533805A/ja active Pending
- 2019-08-23 US US17/250,712 patent/US12290574B2/en active Active
- 2019-08-23 MX MX2021002198A patent/MX2021002198A/es unknown
- 2019-08-26 TW TW108130505A patent/TW202012425A/zh unknown
-
2024
- 2024-04-04 JP JP2024060919A patent/JP2024102065A/ja active Pending
-
2025
- 2025-06-04 AU AU2025204161A patent/AU2025204161A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021533805A5 (https=) | ||
| JP2024009857A5 (https=) | ||
| CN111902539B (zh) | 杂合调控元件 | |
| EP3313991B1 (en) | Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues | |
| JP2022508182A5 (https=) | ||
| JP7541027B2 (ja) | 筋肉発現のためのハイブリッドプロモーター | |
| TW201840850A (zh) | 腺相關病毒載體遞送肌肉特異性微小肌縮蛋白以治療肌肉萎縮症 | |
| JP7430898B2 (ja) | 多発性硬化症のためのａａｖ系遺伝子療法 | |
| JP2020533276A5 (https=) | ||
| JP7702949B2 (ja) | ヒトｍｅｃｐ２遺伝子を発現するように設計されたトランスジーンカセット | |
| JP2022523679A5 (https=) | ||
| US20020076754A1 (en) | Overcoming AAV vector size limitation through viral DNA hetero-dimerization | |
| JP2022551744A5 (https=) | ||
| JP2021520811A5 (https=) | ||
| JP2022536338A (ja) | Ａｒｓａ遺伝子移入のためのアデノ随伴ウイルス組成物およびその使用方法 | |
| CN113891712A (zh) | 用于晚期婴儿神经元蜡样脂褐质沉积症2型的aav载体治疗方法 | |
| JP2024529540A (ja) | 筋肉及びｃｎｓにおける遺伝子発現のためのハイブリッドプロモーター | |
| WO2021078834A1 (en) | Chimeric acid-alpha glucosidase polypeptides and uses thereof | |
| JP2022514271A5 (https=) | ||
| JP7826334B2 (ja) | 髄腔内送達によってピット・ホプキンス症候群を治療するためのメチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルス | |
| TH2201002179A (th) | แคสเสตการถ่ายโอน aav | |
| HK40115222A (zh) | 腺相关病毒载体递送肌肉特异性微肌营养不良蛋白以治疗肌营养不良症 | |
| JP2025534651A (ja) | 呼吸困難を伴う脊髄性筋萎縮１型（ｓｍａｒｄ１）及びシャルコー・マリー・トゥース２ｓ型（ｃｍｔ２ｓ）を治療するためのアデノ随伴ウイルス送達 | |
| HK40126715A (zh) | 用於治疗肌营养不良的肌肉特异性微小肌营养不良蛋白的腺相关病毒载体递送 | |
| EP4472674A1 (en) | Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy associated with friedreich ataxia |